Tags

Type your tag names separated by a space and hit enter

Primary and secondary prevention of stroke by antihypertensive drug treatment.
Expert Rev Neurother. 2004 Nov; 4(6):1023-31.ER

Abstract

Hypertension is the most powerful risk factor for stroke. Antihypertensive drug treatment reduces the incidence of stroke. In a meta-analysis of actively controlled trials, calcium-channel blockers, including (-8%; p = 0.07) or excluding verapamil (-10%; p = 0.02), as well as angiotensin Type 1 receptor blockers (-24%; p = 0.0002) resulted in better stroke prevention than the old drugs (diuretics or beta-blockers), whereas the opposite trend was observed for angiotensin-converting enzyme inhibitors (+10%; p = 0.03). An overview of six trials conducted in patients with a history of cerebrovascular disease demonstrated that blood pressure-lowering therapy reduced stroke recurrence by 25% (p = 0.004). A meta-regression analysis showed that within-trial differences in systolic blood pressure accounted for the prevention of stroke in most trials. This finding was corroborated by the recently published Valsartan Antihypertensive Long-term Use Evaluation trial.

Authors+Show Affiliations

Center for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Institute of Hypertension, Ruijin 2nd Road 197, Shanghai 200025, China. jiguangwang@netscape.netNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15853529

Citation

Wang, Ji-Guang, and Yan Li. "Primary and Secondary Prevention of Stroke By Antihypertensive Drug Treatment." Expert Review of Neurotherapeutics, vol. 4, no. 6, 2004, pp. 1023-31.
Wang JG, Li Y. Primary and secondary prevention of stroke by antihypertensive drug treatment. Expert Rev Neurother. 2004;4(6):1023-31.
Wang, J. G., & Li, Y. (2004). Primary and secondary prevention of stroke by antihypertensive drug treatment. Expert Review of Neurotherapeutics, 4(6), 1023-31.
Wang JG, Li Y. Primary and Secondary Prevention of Stroke By Antihypertensive Drug Treatment. Expert Rev Neurother. 2004;4(6):1023-31. PubMed PMID: 15853529.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Primary and secondary prevention of stroke by antihypertensive drug treatment. AU - Wang,Ji-Guang, AU - Li,Yan, PY - 2005/4/28/pubmed PY - 2006/4/15/medline PY - 2005/4/28/entrez SP - 1023 EP - 31 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 4 IS - 6 N2 - Hypertension is the most powerful risk factor for stroke. Antihypertensive drug treatment reduces the incidence of stroke. In a meta-analysis of actively controlled trials, calcium-channel blockers, including (-8%; p = 0.07) or excluding verapamil (-10%; p = 0.02), as well as angiotensin Type 1 receptor blockers (-24%; p = 0.0002) resulted in better stroke prevention than the old drugs (diuretics or beta-blockers), whereas the opposite trend was observed for angiotensin-converting enzyme inhibitors (+10%; p = 0.03). An overview of six trials conducted in patients with a history of cerebrovascular disease demonstrated that blood pressure-lowering therapy reduced stroke recurrence by 25% (p = 0.004). A meta-regression analysis showed that within-trial differences in systolic blood pressure accounted for the prevention of stroke in most trials. This finding was corroborated by the recently published Valsartan Antihypertensive Long-term Use Evaluation trial. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/15853529/Primary_and_secondary_prevention_of_stroke_by_antihypertensive_drug_treatment_ L2 - http://www.tandfonline.com/doi/full/10.1586/14737175.4.6.1023 DB - PRIME DP - Unbound Medicine ER -